Cargando…
Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax
The S184 residue of Bax is the target of several protein kinases regulating cell fate, including AKT. It is well-established that, in cellulo, the substitution of S184 by a non-phosphorylatable residue stimulates both the mitochondrial localization of Bax, cytochrome c release, and apoptosis. Howeve...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892840/ https://www.ncbi.nlm.nih.gov/pubmed/36741728 http://dx.doi.org/10.3389/fonc.2022.1068994 |
_version_ | 1784881396995588096 |
---|---|
author | Simonyan, Lilit Gonin, Mathilde Hanks, James Friedlein, Jordan Dutrec, Kevin Arokium, Hubert Rouchidane Eyitayo, Akandé Doudy, Toukounou Megann Chaignepain, Stéphane Manon, Stéphen Dejean, Laurent |
author_facet | Simonyan, Lilit Gonin, Mathilde Hanks, James Friedlein, Jordan Dutrec, Kevin Arokium, Hubert Rouchidane Eyitayo, Akandé Doudy, Toukounou Megann Chaignepain, Stéphane Manon, Stéphen Dejean, Laurent |
author_sort | Simonyan, Lilit |
collection | PubMed |
description | The S184 residue of Bax is the target of several protein kinases regulating cell fate, including AKT. It is well-established that, in cellulo, the substitution of S184 by a non-phosphorylatable residue stimulates both the mitochondrial localization of Bax, cytochrome c release, and apoptosis. However, in in vitro experiments, substituted mutants did not exhibit any increase in their binding capacity to isolated mitochondria or liposomes. Despite exhibiting a significant increase of the 6A7 epitope exposure, substituted mutants remain limited in their ability to form large oligomers, suggesting that they high capacity to promote apoptosis in cells was more related to a high content than to an increased ability to form large pores in the outer mitochondrial membranes. |
format | Online Article Text |
id | pubmed-9892840 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98928402023-02-03 Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax Simonyan, Lilit Gonin, Mathilde Hanks, James Friedlein, Jordan Dutrec, Kevin Arokium, Hubert Rouchidane Eyitayo, Akandé Doudy, Toukounou Megann Chaignepain, Stéphane Manon, Stéphen Dejean, Laurent Front Oncol Oncology The S184 residue of Bax is the target of several protein kinases regulating cell fate, including AKT. It is well-established that, in cellulo, the substitution of S184 by a non-phosphorylatable residue stimulates both the mitochondrial localization of Bax, cytochrome c release, and apoptosis. However, in in vitro experiments, substituted mutants did not exhibit any increase in their binding capacity to isolated mitochondria or liposomes. Despite exhibiting a significant increase of the 6A7 epitope exposure, substituted mutants remain limited in their ability to form large oligomers, suggesting that they high capacity to promote apoptosis in cells was more related to a high content than to an increased ability to form large pores in the outer mitochondrial membranes. Frontiers Media S.A. 2023-01-19 /pmc/articles/PMC9892840/ /pubmed/36741728 http://dx.doi.org/10.3389/fonc.2022.1068994 Text en Copyright © 2023 Simonyan, Gonin, Hanks, Friedlein, Dutrec, Arokium, Rouchidane Eyitayo, Doudy, Chaignepain, Manon and Dejean https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Simonyan, Lilit Gonin, Mathilde Hanks, James Friedlein, Jordan Dutrec, Kevin Arokium, Hubert Rouchidane Eyitayo, Akandé Doudy, Toukounou Megann Chaignepain, Stéphane Manon, Stéphen Dejean, Laurent Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax |
title | Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax |
title_full | Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax |
title_fullStr | Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax |
title_full_unstemmed | Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax |
title_short | Non-phosphorylatable mutants of Ser184 lead to incomplete activation of Bax |
title_sort | non-phosphorylatable mutants of ser184 lead to incomplete activation of bax |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9892840/ https://www.ncbi.nlm.nih.gov/pubmed/36741728 http://dx.doi.org/10.3389/fonc.2022.1068994 |
work_keys_str_mv | AT simonyanlilit nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT goninmathilde nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT hanksjames nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT friedleinjordan nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT dutreckevin nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT arokiumhubert nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT rouchidaneeyitayoakande nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT doudytoukounoumegann nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT chaignepainstephane nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT manonstephen nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax AT dejeanlaurent nonphosphorylatablemutantsofser184leadtoincompleteactivationofbax |